LabCorp Expands Partnership with Perinatal Quality Foundation to Educate Patients & Healthcare Providers about Noninvasive Pr...
September 03 2015 - 8:45AM
Business Wire
PQF and LabCorp Build On Established
Collaboration that Promotes Appropriate Use of Innovative
Technologies in Clinical Care
Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:
LH) announced today an expansion of its long-standing partnership
with the Perinatal Quality Foundation (PQF) to collaborate on a new
strategic initiative focused on noninvasive prenatal screening, the
Genetic Education Module (GEM).
PQF’s GEM initiative will provide education to help patients and
healthcare providers better understand the benefits and limitations
of noninvasive prenatal screening and how to interpret the results
of that screening. GEM will also build a patient registry designed
to correlate the results of noninvasive prenatal testing with the
results of confirmatory diagnostic tests, such as chorionic villus
sampling (CVS) or amniocentesis, as well as post-partum outcomes.
In addition, the initiative will help develop processes for
credentialing healthcare personnel in the delivery of pre- and
post- screening information. LabCorp and PQF are committed to
improve patient outcomes and lives, while lowering costs, through
expanded access to emerging healthcare technologies, such as their
existing work on PQF’s Nuchal Translucency Quality Review program,
which provides education and credentialing for sonographers and
physicians involved in first trimester risk assessment.
"As new genetic technologies enter the market, it is imperative
for industry leaders, such as LabCorp, to foster the use of genetic
information and support the appropriate administration and
interpretation of these technologies,” said Dr. Ron Wapner and Dr.
Larry Platt, members of the PQF board of directors. “LabCorp is one
of the founding supporters of PQF, and we welcome LabCorp’s
continued assistance in helping PQF meet its objectives of
educating patients and providers."
“As a leader in integrated genetic testing and counseling
services, we are proud to support another important PQF objective,
facilitating physician and patient access to much-needed resources
focused on noninvasive prenatal screening," stated Dr. Marcia
Eisenberg, LabCorp Diagnostics’ Chief Scientific Officer. “Genetic
testing is a rapidly evolving area of medicine, and by working
collaboratively with organizations like PQF, we can advance access
to, and understanding of, high-quality test results for physicians
and the patients they serve.”
LabCorp is a leader in women’s health and specialty genetics,
and has extensive experience developing and commercializing
innovative maternal diagnostic testing services, including
noninvasive prenatal screening, the SNP microarray and expanded
carrier screening, that is changing the way care is provided.
LabCorp also offers integrated complementary services to testing,
such as clinical programs for maternal serum screening,
cytogenetics, single gene testing and the industry’s largest team
of genetic counselors, who support patients and their physicians
with analysis, assessment, and interpretation of genetic test
results.
About LabCorp®
Laboratory Corporation of America® Holdings, an S&P 500
company, is the world’s leading healthcare diagnostics company,
providing comprehensive clinical laboratory services through
LabCorp Diagnostics, and end-to-end drug development support
through Covance Drug Development. LabCorp is a pioneer in
commercializing new diagnostic technologies and is improving
people’s health by delivering the combination of world-class
diagnostics, drug development and knowledge services. With combined
revenue pro forma for the acquisition of Covance in excess of $8.5
billion in 2014 and more than 48,000 employees in over 60
countries, LabCorp offers innovative solutions to healthcare
stakeholders. LabCorp clients include physicians, patients and
consumers, biopharmaceutical companies, government agencies,
managed care organizations, hospitals, and clinical labs. To learn
more about Covance Drug Development, visit www.covance.com. To
learn more about LabCorp and LabCorp Diagnostics, visit
www.labcorp.com.
This press release contains forward-looking statements including
with respect to estimated 2015 guidance and the impact of various
factors on operating results. Each of the forward-looking
statements is subject to change based on various important factors,
including without limitation, competitive actions in the
marketplace, adverse actions of governmental and other third-party
payers and the results from the Company’s acquisition of Covance.
Actual results could differ materially from those suggested by
these forward-looking statements. Further information on potential
factors that could affect LabCorp’s operating and financial results
is included in the Company’s Form 10-K for the year ended December
31, 2014, and the Company’s Form 10-Q for the quarter ended June
30, 2015, including in each case under the heading risk factors,
and in the Company’s other filings with the SEC, as well as in the
risk factors included in Covance’s filings with the SEC. The
information in this press release should be read in conjunction
with a review of the Company’s filings with the SEC including the
information in the Company’s Form 10-K for the year ended December
31, 2014, and subsequent Forms 10-Q, under the heading MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS.
About PQF
The Perinatal Quality Foundation was incorporated in Washington,
D.C. in 2004 and in Oklahoma in 2010. It is an independent
non-profit foundation. The mission of the Perinatal Quality
Foundation is to improve the quality of Maternal-Fetal medicine
medical services by providing state of the art educational
programs, and evidence-based, statistically valid monitoring
systems to evaluate current practices and facilitate the transition
of emerging technologies into clinical care. The foundation is
committed to disseminating safe and excellent obstetrical practice
protocols, and to providing clinician and provider education,
monitoring measures, and consensus discussions on emerging
obstetrical technologies. www.perinatalquality.org
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150903005217/en/
LabCorp®Paul Surdez, 336-436-5076Company Information:
www.labcorp.com
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Apr 2023 to Apr 2024